{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T16:37:59Z","timestamp":1761323879017},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Psychosomatic Research"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.jpsychores.2013.02.005","type":"journal-article","created":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T05:52:09Z","timestamp":1365054729000},"page":"454-457","source":"Crossref","is-referenced-by-count":7,"title":["Improving depression and reducing cardiac events: Which is the chicken and which is the egg?"],"prefix":"10.1016","volume":"74","author":[{"given":"Roy C.","family":"Ziegelstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychores.2013.02.005_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/nrendo.2012.238","article-title":"HDL\u2014is it too big to fail?","author":"Ng","year":"2013","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jpsychores.2012.11.008","article-title":"Depression treatment and coronary artery disease outcomes: time for reflection","volume":"74","author":"Shapiro","year":"2013","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0015","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1161\/01.CIR.0000087480.94275.97","article-title":"From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I","volume":"108","author":"Naghavi","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0020","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1161\/01.CIR.0000041255.88750.F0","article-title":"Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging","volume":"106","author":"Corti","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0025","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1161\/01.CIR.0000097067.96619.1F","article-title":"Characterizing vulnerable plaque features with intravascular elastography","volume":"108","author":"Schaar","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0030","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1161\/01.CIR.0000131887.65955.3B","article-title":"Incidence of high-strain patterns in human coronary arteries: assessment with three-dimensional intravascular palpography and correlation with clinical presentation","volume":"109","author":"Schaar","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0035","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1002358","article-title":"A prospective natural-history study of coronary atherosclerosis","volume":"364","author":"Stone","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0040","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1006\/jmcc.1999.1049","article-title":"Heat production of atherosclerotic plaques and inflammation assessed by the acute phase proteins in acute coronary syndromes","volume":"32","author":"Stefanadis","year":"2000","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0045","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1192\/bjp.bp.106.028647","article-title":"MIND-IT investigators. Effects of antidepressant treatment following myocardial infarction","volume":"190","author":"van Melle","year":"2007","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0050","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1001\/jama.289.23.3106","volume":"289","author":"Berkman","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0055","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/jama.288.6.701","article-title":"Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina","volume":"288","author":"Glassman","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0060","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/rheumatology\/keq327","article-title":"Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis","volume":"50","author":"Kekow","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0065","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","article-title":"Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial","volume":"367","author":"Tyring","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0070","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.1365-2133.2007.08205.x","article-title":"Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96weeks","volume":"157","author":"Krishnan","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0075","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/j.1468-3083.2011.04308.x","article-title":"Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens","volume":"26","author":"Gniadecki","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0008-6363(01)00434-5","article-title":"The inflammatory response in myocardial infarction","volume":"53","author":"Frangogiannis","year":"2002","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0085","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/01.CIR.94.5.874","article-title":"Elevated levels of interleukin-6 in unstable angina","volume":"94","author":"Biasucci","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0090","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10741-009-9140-3","article-title":"Biomarkers of inflammation in heart failure","volume":"15","author":"Bozkurt","year":"2010","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0095","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0735-1097(00)01121-9","article-title":"Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy","volume":"37","author":"Ohtsuka","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0100","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S0735-1097(99)00594-X","article-title":"Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure","volume":"35","author":"Tsutamoto","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0105","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/S0735-1097(99)00495-7","article-title":"Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure","volume":"34","author":"Gullestad","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0110","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/PSY.0b013e3181907c1b","article-title":"Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis","volume":"71","author":"Howren","year":"2009","journal-title":"Psychosom Med"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0115","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.biopsych.2009.09.033","article-title":"A meta-analysis of cytokines in major depression","volume":"67","author":"Dowlati","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0120","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/sj.mp.4001805","article-title":"The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine","volume":"11","author":"M\u00fcller","year":"2006","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0130","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.amjcard.2004.07.127","article-title":"Comparison of circulating proinflammatory cytokines and soluble apoptosis mediators in patients with chronic heart failure with versus without symptoms of depression","volume":"94","author":"Parissis","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0135","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.thromres.2011.05.022","article-title":"Influence of cardiac resynchronization therapy on indices of inflammation, the prothrombotic state and tissue remodeling in systolic heart failure: a pilot study","volume":"128","author":"Mar\u00edn","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0140","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1540-8159.2006.00331.x","article-title":"Antiinflammatory effects of cardiac resynchronization therapy in patients with chronic heart failure","volume":"29","author":"Theodorakis","year":"2006","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0145","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.clinbiochem.2012.11.002","article-title":"Cardiac resynchronization therapy in patients with chronic heart failure is associated with anti-inflammatory and anti-remodeling effects","volume":"46","author":"Stanciu","year":"2013","journal-title":"Clin Biochem"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0150","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1540-8159.2006.00430.x","article-title":"Anti-inflammatory effect of cardiac resynchronization therapy","volume":"29","author":"Lappeg\u00e5rd","year":"2006","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0155","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cardfail.2006.11.013","article-title":"Relation of inflammatory status to major adverse cardiac events and reverse remodeling in patients undergoing cardiac resynchronization therapy","volume":"13","author":"Michelucci","year":"2007","journal-title":"J Card Fail"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0160","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1540-8167.2011.02258.x","article-title":"Depression and severe heart failure: benefits of cardiac resynchronization therapy","volume":"23","author":"Ploux","year":"2012","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0165","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/archinternmed.2011.2321","article-title":"Mounting evidence for lack of PCI benefit in stable ischemic heart disease: what more will it take to turn the tide of treatment?","volume":"172","author":"Boden","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0170","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1056\/NEJM199812173392511","article-title":"Inotropic therapy for heart failure","volume":"339","author":"Stevenson","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0175","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0002-9149(84)90299-6","article-title":"The MILIS Study Group. Risk factors for sudden death after acute myocardial infarction: two-year follow-up","volume":"54","author":"Mukharji","year":"1984","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0180","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/0002-9149(88)90754-0","article-title":"Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS","volume":"61","author":"The Cardiac Arrhythmia Pilot Study (CAPS) Investigators","year":"1988","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0185","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJM199207233270403","article-title":"Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction","volume":"327","author":"The Cardiac Arrhythmia Suppression Trial II Investigators","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0190","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial","volume":"324","author":"Echt","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0195","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1093\/oxfordjournals.eurheartj.a014714","article-title":"Effects of captopril on ventricular arrhythmias in the early and late phase of suspected acute myocardial infarction. Randomized, placebo-controlled substudy of ISIS-4","volume":"17","author":"Budaj","year":"1996","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0200","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1161\/01.CIR.90.1.101","article-title":"Ventricular arrhythmias in the acute and chronic phases after acute myocardial infarction. Effect of intervention with captopril","volume":"90","author":"S\u00f8gaard","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0205","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1001\/jama.1993.03510200057032","article-title":"Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST)","volume":"270","author":"Epstein","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.jpsychores.2013.02.005_bb0210","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0735-1097(98)00609-3","article-title":"Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials","volume":"33","author":"Domanski","year":"1999","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Psychosomatic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022399913000470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022399913000470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T06:32:36Z","timestamp":1539757956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022399913000470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0022399913000470"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychores.2013.02.005","relation":{},"ISSN":["0022-3999"],"issn-type":[{"value":"0022-3999","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}